Update on Alzheimer's appraisal

The National Institute for Health and Clinical Excellence (NICE) has requested more evidence from pharmaceutical companies before publishing the final draft of its review of donepezil, rivastigmine, galantamine and memantine for the treatment Alzheimer's disease.

Further information on the appraisal of Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review).